Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer

被引:27
|
作者
Monge, A
Jagla, M
Lapouge, G
Sasorith, S
Cruchant, M
Wurtz, JM
Jacqmin, D
Bergerat, JP
Céraline, J
机构
[1] Univ Strasbourg 1, Lab Cancerol Expt & Radiobiol, EA 3430, IRCAD, F-67091 Strasbourg, France
[2] IGBMC, Dept Biol & Genom Struct, Illkirch Graffenstaden, France
[3] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France
[4] Hop Univ Strasbourg, Serv Chirurg Urol, Strasbourg, France
关键词
androgen receptor; hormone-refractory prostate cancer; mutation; DNA binding specificity; transcriptional activity;
D O I
10.1007/s00018-005-5471-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Missense mutations in the androgen receptor (AR) contribute to the failure of hormonal therapy for prostate cancer (PCa), but the underlying molecular bases remain uncharacterized. Here, we describe a new AR variant found in a hormone-refractory metastatic PCa, in which threonine 575 in the DNA binding domain, and threonine 877 in the ligand-binding domain, were both replaced by an alanine. Using gene reporter assays, we demonstrate that the T575A mutation weakened transcriptional activity from promoters containing AR-spe-cific responsive elements, while activity from promoters with AR-non-specific elements was enhanced. Data from gel shift experiments revealed a preferential binding of the T575A mutant to AR-non-specific motifs. We demonstrate that the two mutations T575A and T877A cooperate to confer new functional properties on the AR, and that the mutant AR functions simultaneously as a promiscuous AR due to the T877A mutation, and an unfaithful AR due to the T575A mutation.
引用
收藏
页码:487 / 497
页数:11
相关论文
共 50 条
  • [31] Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
    Hu, Rong
    Dunn, Thomas A.
    Wei, Shuanzeng
    Isharwal, Sumit
    Veltri, Robert W.
    Humphreys, Elizabeth
    Han, Misop
    Partin, Alan W.
    Vessella, Robert L.
    Isaacs, William B.
    Bova, G. Steven
    Luo, Jun
    CANCER RESEARCH, 2009, 69 (01) : 16 - 22
  • [32] Role of PSA Kinetics in Hormone-refractory Prostate Cancer
    Sabur, Volkan
    Untan, Ibrahim
    Tatlisen, Atila
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2021, 31 (06): : 673 - 678
  • [33] Current topics in the treatment of hormone-refractory prostate cancer
    Iversen, P
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 3 - 8
  • [34] Role of androgen receptors in hormone-refractory prostate cancer.: Molecular basics and experimental therapy approaches
    Rinnab, L.
    Hessenauer, A.
    Schuetz, S. V.
    Schmid, E.
    Kuefer, R.
    Finter, F.
    Hautmann, R. E.
    Spindler, K. D.
    Cronauer, M. V.
    UROLOGE, 2008, 47 (03): : 314 - +
  • [35] Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in Indian population
    Mittal, Rama Devi
    Mishra, Dhruva K.
    Mandhani, Anil
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2007, 8 (02) : 275 - 278
  • [36] Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer
    Uemura H.
    Hasumi H.
    Kawahara T.
    Sugiura S.
    Miyoshi Y.
    Nakaigawa N.
    Teranishi J.-I.
    Noguchi K.
    Ishiguro H.
    Kubota Y.
    International Journal of Clinical Oncology, 2005, 10 (6) : 405 - 410
  • [37] Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
    J Edwards
    N S Krishna
    K M Grigor
    J M S Bartlett
    British Journal of Cancer, 2003, 89 : 552 - 556
  • [38] Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
    Edwards, J
    Krishna, NS
    Grigor, KM
    Bartlett, JMS
    BRITISH JOURNAL OF CANCER, 2003, 89 (03) : 552 - 556
  • [39] Maspin Enhances the Anticancer Activity of Curcumin in Hormone-refractory Prostate Cancer Cells
    Cheng, Wan-Li
    Huang, Chien-Yu
    Tai, Cheng-Jeng
    Chang, Yu-Jia
    Hung, Chin-Sheng
    ANTICANCER RESEARCH, 2018, 38 (02) : 863 - 870
  • [40] Looking to the future: Advances in the management of hormone-refractory prostate cancer
    Trachtenberg, J
    Blackledge, G
    EUROPEAN UROLOGY SUPPLEMENTS, 2002, 1 (07) : 44 - 53